2025年8月29日，普蕊斯（上海）医药科技开发股份有限公司在上海公司会议室，举行了由国泰海通证 券、中金公司等8家证券联合主持的2025年年报业绩交流电话会，易方达基金、华夏基金等46家机构共 56人参与。普蕊斯总经理杨宏伟、董事会秘书赖小龙接待了来访机构。 普蕊斯作为大数据驱动型临床研究服务商，2025年上半年实现营业收入39,010.09万元；归属于上市公司 股东的净利润5,415.61万元；归属于上市公司股东的扣除非经常性损益的净利润3,854.45万元。尽管一季 度业绩阶段性承压，但二季度随着客户需求复苏及精细化运营管理措施落地，营业收入及盈利水平同比 向好、环比显著改善。二季度营业收入同比增长1.82%，环比增长21.06%；净利润同比增长45.17%，环 比增长528.73%；扣除非经常性损益的净利润同比增长16.98%，环比增长598.63% 。 从行业需求看，中国创新药产业变革突破，2015 - 2024年自主研发创新药超700个居全球首位，原研首 创药物研发管线数量全球第二。2024年临床试验登记与信息公示平台登记临床试验同比增长21%，2025 年上半年1类新药批准同比增长59%，反映行 ...

证券代码：301257 证券简称：普蕊斯 普蕊斯（上海）医药科技开发股份有限公司 投资者关系活动记录表 编号：2025-008 投资者关系 活动类别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □券商策略会 其他 （国泰海通证券、中金公司、华创证券、信达证券、中泰证券、 华安证券、东北证券、国盛证券 8 家证券联合主持的 2025 年半 年报业绩交流电话会） 参与单位 名称及人员 姓名 易方达基金 华夏基金 天弘基金 浦银安盛基金 博远基金 诺安基金 博道基金 华泰资管 慎知资管 晨壹投资 磐石投资 中昂国际投资 永诚财产保险 太平资管 丹羿投资 英大国际信托 国泰海通证券 中金公司 华创证券 信达证券 中泰证券 华安证券 东北证券 国盛证券 兴业证券 东方证券 国海证券 申万宏源证券 长城国瑞证券 光大证券 长江证券 太平洋证券 招商证券 山西证券 等 46 家机构 56 人 时间 2025 年 8 月 29 日 地点 上海公司会议室 上市公司接 待人员姓名 总经理 杨宏伟 董事会秘书 赖小龙 一、介绍公司 2025 年上半年度经营情况 普蕊斯是一家大数据驱 ...

Market Overview - The medical services sector rose by 3.64% on August 29, with the leading stock being Puris [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Top Gainers in Medical Services - Zenggansi (301257) closed at 43.54, up 20.01% with a trading volume of 64,900 shares and a turnover of 278 million [1] - Haoyuan Pharmaceutical (688131) closed at 68.48, up 13.70% with a trading volume of 189,200 shares and a turnover of 1.256 billion [1] - Bidai Pharmaceutical (688073) closed at 67.11, up 10.43% with a trading volume of 28,300 shares and a turnover of 182 million [1] - Meidi Xi (688202) closed at 64.21, up 8.96% with a trading volume of 124,400 shares and a turnover of 784 million [1] - WuXi AppTec (603259) closed at 103.30, up 7.95% with a trading volume of 1,016,600 shares and a turnover of 10.18 billion [1] Top Losers in Medical Services - Digital Human (835670) closed at 17.54, down 6.20% with a trading volume of 127,200 shares and a turnover of 227 million [2] - Puri Eye Hospital (301239) closed at 40.78, down 4.63% with a trading volume of 49,600 shares and a turnover of 203 million [2] - Yingkang Life (300143) closed at 10.64, down 3.45% with a trading volume of 230,300 shares and a turnover of 250 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 1.259 billion from institutional investors, while retail investors experienced a net outflow of 446 million [2][3] - Major stocks like WuXi AppTec had a net inflow of 1.269 billion from institutional investors, while it faced a net outflow of 741 million from retail investors [3]

29日，医药生物板块回暖，创新药概念股震荡反弹，普蕊斯（301257）"20cm"涨停，报43.54元/股。截至发稿，换手率8.56%，成 交额2.76亿元。 据了解，普蕊斯是一家大数据驱动型临床研究服务商，专注于为全球制药公司、医疗器械公司、CRO公司等提供高效、合规的临 床试验现场管理组织(SMO)服务，帮助客户提升临床试验的执行效率和数据质量，助力新药更快惠及患者。 公司主要客户为国际药企或国内知名创新型药企，与2024年全球前10大药企均有合作，为包括阿斯利康、艾昆纬、百时美施贵 宝、百利天恒、百济神州、迪哲、复星医药（600196）、恒瑞、豪森、精鼎、君实、康方、科伦、罗氏、礼来、默沙东、诺华、 强生、三生国健、宜联生物、映恩等在内的知名药企和CRO提供临床试验现场管理工作，具备较为突出的优质创新药企服务能 力，提供的SMO服务质量高、效率高，处于同行业先进水平。 28日，普蕊斯披露了2025年半年度报告。报告显示，第二季度，公司单季度主营收入为2.14亿元，同比上升1.82%；单季度归母 净利润为4672.45万元，同比增长45.17%；单季度扣非净利润为3371.81万元，同比上升16.98%。 ...

Group 1 - The A-share CRO (Contract Research Organization) sector experienced a significant rally on August 29, with notable stock price increases [1] - Haoyuan Pharmaceutical surged over 14%, while Medices and Chengdu Xian Dao saw increases of over 10% and 9% respectively [1] - Other companies such as Pruis and Boteng Co., along with Inno Laser, also showed positive performance in the market [1]

Core Viewpoint - The innovative pharmaceutical stocks experienced a significant rebound, with Huahai Pharmaceutical and Kangchen Pharmaceutical both hitting the daily limit up, indicating strong market interest and investor confidence in the sector [1] Industry Summary - The National Medical Products Administration of China reported that the country's pharmaceutical industry ranks second globally, with approximately 30% of the world's innovative drugs currently under research [1] - Since the beginning of the 14th Five-Year Plan, a total of 387 pediatric drugs and 147 rare disease drugs have been approved for market, effectively addressing the medication needs of key populations [1] Company Summary - Huahai Pharmaceutical and Kangchen Pharmaceutical both reached the daily limit up, reflecting positive market sentiment towards their stock performance [1] - Other companies such as Puris, Duolai Pharmaceutical, Haoyuan Pharmaceutical, Huana Pharmaceutical, Medisi, Lifang Pharmaceutical, and Guangshengtang also saw stock increases, with some rising over 5% [1]

Group 1 - The core viewpoint of the news is that Prasis has experienced a decline in stock price and trading volume, with significant changes in financing and shareholder structure [1][2]. - As of August 28, Prasis' stock price fell by 1.44%, with a trading volume of 88.46 million yuan, and a net financing outflow of 725,800 yuan [1]. - The total financing and securities balance for Prasis is 64.34 million yuan, which is 2.24% of its market capitalization, indicating a low financing level compared to the past year [1]. Group 2 - As of July 31, the number of shareholders for Prasis decreased by 7.55% to 8,735, while the average circulating shares per person increased by 8.16% to 8,622 shares [2]. - For the first half of 2025, Prasis reported a revenue of 390 million yuan, a year-on-year decrease of 1.08%, and a net profit attributable to shareholders of 54.16 million yuan, down 1.40% year-on-year [2]. - Since its A-share listing, Prasis has distributed a total of 40.77 million yuan in dividends [3].

证券日报网讯 8月28日晚间，普蕊斯发布公告称，公司第三届监事会第十四次会议审议通过了《关于公 司及其摘要的议案》等。 （文章来源：证券日报） ...

证券日报网讯 8月28日晚间，普蕊斯发布公告称，公司第三届董事会第十四次会议审议通过了《关于公 司的议案》等。 （文章来源：证券日报） ...

智通财经APP讯，普蕊斯(301257.SZ)发布2025年半年度报告，该公司营业收入为3.9亿元，同比减少 1.08%。归属于上市公司股东的净利润为5415.61万元，同比减少1.40%。归属于上市公司股东的扣除非 经常性损益的净利润为3854.45万元，同比减少20.35%。基本每股收益为0.69元。 （原标题：普蕊斯(301257.SZ)发布上半年业绩，归母净利润5415.61万元，下降1.40%） ...